OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism ...

Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock ...

Cardinal Health's CAH pharmaceutical segment has consistently demonstrated resilience and growth, driven by strong demand ...

Titled “State of the Industry—The Evolving Landscape of Healthcare Coverage and Access in 2025,” 1 the goal of the Access USA ...

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...

AmerisourceBergen Corp is a pharmaceutical services company. It provides drug distribution and related healthcare services and solutions to pharmacy, physician, and manufacturer customers based in the ...

Cencora (NYSE:COR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is updating its model following Cencora’s results and ...

Pictures of hives, also known as urticaria, can help you to identify these raised, red, itchy bumps or welts. Causes include stress, infections, food or latex allergies, medications, and environmental ...

Cencora has a 12 month low of $214.77 and a 12 month high of $263.70. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Shares of Cencora Inc. COR slid 2.56% to $254.00 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to 5,599.30 and ...